Retension Pharmaceuticals (NASDAQ:RTSN) Coverage Initiated by Analysts at Leerink Partners

Equities researchers at Leerink Partners began coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN) in a research report issued on Tuesday, Zacks reports. The firm set a “strong-buy” rating on the stock.

Several other analysts have also commented on RTSN. Guggenheim initiated coverage on shares of Retension Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $55.00 price objective on the stock. Oppenheimer initiated coverage on shares of Retension Pharmaceuticals in a research report on Tuesday. They set an “outperform” rating and a $50.00 target price for the company. One analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $52.50.

Retension Pharmaceuticals Stock Down 1.6%

Shares of NASDAQ:RTSN opened at $11.60 on Tuesday. Retension Pharmaceuticals has a fifty-two week low of $9.66 and a fifty-two week high of $18.64.

Insider Buying and Selling at Retension Pharmaceuticals

In other news, Director Franklin M. Berger purchased 10,000 shares of the business’s stock in a transaction dated Tuesday, October 13th. The stock was bought at an average price of $12.00 per share, for a total transaction of $120,000.00. Following the purchase, the director owned 10,000 shares of the company’s stock, valued at $120,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric L. Keller acquired 20,800 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The stock was purchased at an average cost of $12.00 per share, with a total value of $249,600.00. Following the acquisition, the chief executive officer owned 423,377 shares in the company, valued at $5,080,524. The trade was a 5.17% increase in their position. The SEC filing for this purchase provides additional information.

About Retension Pharmaceuticals

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.